Slides
Page 1
2026 | Half-year results Matthias Schupp, CEO | Peter Hackel, CFO Basel, 18 August 2026
Page 2
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Medartis Holding AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions. Further, neither the company nor any of its directors, officers, employees, agents, counsel or advisers nor any other person makes any representation or warranty, express or implied, as to the accuracy or completeness of the information contained herein or of the views given or implied, and accordingly no reliance should be placed on it. This presentation contains specific forward-looking statements, beliefs or opinions, including statements with respect to the product pipelines, potential benefits of product candidates and objectives, estimated market sizes and opportunities as well as the milestone potential under existing collaboration agreements, which are based on current beliefs, expectations and projections about future events, e.g. statements including terms like “potential”, “believe”, “assume”, “expect”, “fore-cast”, “project”, “may”, “could”, “might”, “will” or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Medartis Holding AG and investments and those explicitly or implicitly presumed in these statements. There are several factors that could cause actual results and developments to differ materially from those expressed or implied by these statements and forecasts. Past performance of Medartis Holding AG cannot be relied on as a guide to future performance. Forward-looking statements speak only as of the date of this presentation and Medartis Holding AG, its directors, officers, employees, agents, counsel and advisers expressly disclaim any obligations or undertaking to release any update of, or revisions to, any forward-looking statements in this presentation. No statement in this document or any related materials or given at this presentation is intended as a profit forecast or a profit estimate and no statement in this document or any related materials or given at this presentation should be interpreted to mean that earnings per share for the current or future financial periods would necessarily match or exceed historical published earnings per share. As a result, you are cautioned not to place any undue reliance on such forward-looking statements. Unless stated otherwise the information provided in this presentation are based on company in-formation. This presentation is intended to provide a general overview of Medartis Holding AG’s business and does not purport to deal with all aspects and details regarding Medartis Holding AG. Accordingly, neither Medartis Holding AG nor any of its directors, officers, employees, agents, counsel or advisers nor any other person makes any representation or warranty, express or implied, as to, and accordingly no reliance should be placed on, the accuracy or completeness of the information contained in the presentation or of the views given or implied. Neither Medartis Holding AG nor any of its directors, officers, employees, agents, counsel or advisers nor any other person shall have any liability whatsoever for any errors or omissions or any loss howsoever arising, directly or indirectly, from any use of this information or its contents or otherwise arising in connection therewith. The material contained in this presentation reflects current legislation and the business and financial affairs of Medartis Holding AG which are subject to change and audit. Disclaimer 2
Page 3
⎼ We are ON TRACK: Organic sales in H1 rose 17.0% and the core EBITDA margin increased to 18.0% ⎼ TOUCH ROLLOUT in the US and Australia now fully under way ⎼ FESSH Congress in Basel and 2nd TOUCH congress showed RECORD ATTENDANCE ⎼ NeoOrthos 'Cold Fusion' project completed: both head offices now consolidated in CURITIBA ⎼ Based on business performance to date, we feel confident to RAISE THE GUIDANCE for the full-year H1 2026 | Delivering on our promises
Page 4
Key highlights │ Keeping our promises 2026 Guidance − Based on business performance to date and outlook for ROY, management lifts the FY guidance RAISED 4 1 Organic growth is calculated using fixed exchange rates (CER). To ensure fair comparison, it includes the acquired business's sales in the baseline figures from the date Medartis assumed control. 2 Core figures exclude certain one-time, nonrecurring and extraordinary items or items related to M&A. For a detailed overview of all non-core events in the Income Statement, please refer to APM section of the Half-year Report. Group revenue 160.8million − Up 30.7% including contributions of CHF 24.3 million from NeoOrtho, Keri Medical and CADskills Organic revenue growth1 − Driven by dynamic growth in the US and further share gains in EMEA − Supported by the intern. expansion of TOUCH® 18.0% core2 − +0.2pp (CHF) or +0.9pp (CER) − Despite FX pressure and additional costs from US tariffs EBITDA margin 17.0% CER CHF
Page 5
5 US and EMEA outpacing 17,0% US 27,4% EMEA 17,7% LATAM 9,6% APAC 5,5% Worldwide
Page 6
Financial review Peter Hackel, CFO
Page 7
-3.7 FX Core sales H1 2026 LATAM 1.5 APAC 0.9 122.1 137.0 US 6.5 EMEACore sales H1 2025 14.3 Adj. core sales H1 2025 CER M&A sales impact 18.6 160.2 Organic 17,0% 17,7% 27,4% 5,4% 9,6% Core sales1 in million CHF and yoy growth rates 1 Core growth excluding the NSI contract manufacturing business and NeoOrtho's disposed hip business. M&A impact relates to the acquisition of Keri Medical, NeoOrtho and CADskills. US and EMEA were the key growth contributors in H1 7
Page 8
Breakdown by category (left) and organic growth in H1 2026 in % (right) 8 − Largest segment UE with dynamic growth driven by strong sales in H&W, high trauma volumes in Europe due to severe winter conditions and expansion of TOUCH implants − Lower extremities growth was driven by strong sales of the ankle trauma set, which offers a compelling alternative to competitor systems − CMF & others impacted by prior-year baseline due to new distributor’s surgical set investment in New Zealand in 2025) Upper extremities driven by H&W portfolio 71% 16% 13% Upper extremities Lower extremities CMF & Others 21.1 10.4 5.5 Upper extremities Lower extremities CMF & others
Page 9
9 US tariffs impact | Mitigation strategy in place ⎼ The core result includes a tariff charge of CHF 0.9 million related to implants sold in H1 2026 (representing an approx. tariff rate of 12.5%) ⎼ In H1 2025 we had no substantial US tariff expenses ⎼ For part of 2025, US tariffs on implants sold were charged at a higher rate than was ultimately due. We have therefore claimed a refund from the US authorities and recognised a receivable of CHF 4.4 million on 30 June 2026, which we expect to collect in Q3 2026. ⎼ The IFRS result includes CHF 1.7 million refunds related to tariffs expensed in 2025 – but refunded in 2026, this leads a net tariff credit of CHF +0.8 million in H1 2026 as refunds from 2025 exceed tariffs charged in H1 core result 2026 ⎼ Medartis expects a tariff rate of 12.5% on products shipped to the US going forward. Measures under ‘Project Flash’ are progressing as planned, with the aim of: • producing 70% of US sales locally by the end of 2026 • lifting onshore production to 80% by mid-2027
Page 10
10 Reconciliation of APMs in H1 2026 − M&A effects: The amortisation of intangible assets of CHF 1.0 million related to historical acquisition effects and are therefore excluded from the core figures. − Non-core business: Negative contribution form the US contract manufacturing business (fading out) and the NeoOrtho hip business (disposed in 2025) − Others (OPEX): OPEX included CHF 1.9 million of transaction costs related to the acquisition of CADskills and legal costs from a full resolved supplier dispute. − Others (Cost of goods sold): trade tariffs on implants exported into the US were charged at a higher rate than was ultimately due. From a total refund of CHF 4.4 million an amount of CHF 1.7 million concerns tariffs for implants sold during the 2025 financial year, and this credit has been excluded from the core result. (in CHF thousands) IFRS 2026.6 M&A effects non-core business Other CORE 2026.6 CORE 2025.6 Net revenue 160’835 - (638) - 160’198 122’050 Cost of goods sold (29’433) 16 1’489 (1’748) (29’677) (23’550) Gross profit 131’402 16 851 (1’748) 130’521 98’500 Gross profit margin 81.7% 81.5% 80.7% Operating expenses (OPEX) (118’948) 1’001 (1) 1’892 (116’056) (89’100) as % of sales -74.0% -72.4% -73.0% Share of results of associate - - - - - 978 Operating profit/(loss) 12’454 1’016 850 144 14’465 10’378 EBIT margin 7.8% 9.0% 8.5% Finance income 3’421 - - - 3’421 759 Finance expense (5’458) - - - (5’458) (9’493) Income/(loss) before taxes 10’416 1’016 850 144 12’427 1’645.07 Income tax expense/income (5’491) (133) (205) 176 (5’654) (2’079) Net income/(loss) 4’925 884 645 320 6’774 (434) Attributable to: Medartis Holding AG shareholders 8’349 800 645 320 10’113 11’423 Non-controlling interests 987 84 - - 1’070 Earnings per share (in CHF): - Basic earnings per share (in CHF) 0.41 - - - 0.54 (0.03) Diluted earnings per share (in CHF) 0.41 - - - 0.54 (0.03) Operating profit/(loss) 12’454 1’016 850 144 14’465 10’378 Depreciation and amortization 15’140 (549) (258) - 14’333 11’391 EBITDA 27’594 468 592 144 28’798 21’769 EBITDA Margin 17.2% 18.0% 17.8%
Page 11
11 Gross margin | Margin +1.4pp on Keri Medical integration and stronger Medartis margin − Gross margin impacted by FX and new US tariffs (0.6pp and 0.6pp) − M&A consolidation effect had a net impact of 0.5pp incl. internalisation of Keri Medical (accretive) and NeoOrtho (slightly dilutive) margin 1.2 0.7 0.7 0.5 0.2 Reported gross margin H1 2025 FX Non-core items Core gross margin PY @CER Medartis Group price & mix M&A consolidation effect US tariffs 79.5 81.5 81.7 Reported gross margin 2025 -0.6 80.1 Non-core items -0.6 Efficiencies Core gross margin H1 2026 +1.4pp in % of net sales, rounded
Page 12
12 EBITDA | Core profitability increased thanks to OPEX leverage − Core EBITDA margin increased +0.9 PP at CER − Investment in growth initiatives while keeping overall cost discipline − NeoOrtho with positive effect on EBITDA margin 0.8 1.4 0.4 Reduced OPEX ratio -0.9 Associate result 18.0 -0.9 Non-core items 17.217.0 Reported EBITDA margin H1 2025 -0.7 Core EBITDA margin H1 2026 FX Non-core items Reported EBITDA margin H1 2026 17.1 Core EBITDA PY margin @CER Gross margin effect +0.9 PP in % of net sales, rounded
Page 13
13 Net result | Bottom-line driven by improved result and FX gains -1.3 -0.4 6.8 4.9 6.7 Non-core items Non-core items Net result H1 2026 Core net profit H1 2025 5.3 Operational result -1.0 Associate result -0.2 Other operating result Finance result -3.6 TaxesReported net profit H1 2025 -1.9 0.9 Core net profit H1 2026 +7.2 − Improved finance result of CHF 6.7 million; mainly attributable to FX despite higher interest expense and finance transaction fees of CHF 1.3 million − Tax expense +CHF 3.6 million consistent with the stronger operating result and the inclusion of Keri Medical. In CHF million
Page 14
14 Free cashflow | FCF at CHF 9 million due to increased CAPEX investments − CAPEX increased due to capacity investments (building and machinery) in various sites − NWC: CHF 4.1 million higher inventory for new surgical sets (inventory) and CHF 4.4 million for unsettled US tariff refund (‘other receivable’) − DSOs remained stable at 59 days compared to year-end level − Cash balance reflecting acquisition of CADskills and CHF 12 million earnout payment for KeriMedical In CHF million Cash Year- end 2025 7.8 Operating cashflow -17.9 CAPEX -14.7 M&A and other investing 17.3 Financing 0.3 FX Cash Mid- year 2026 33.0 25.8 Free cashflow: CHF -10.1 million (PY 0.5 million)
Page 15
15 Strategy update Matthias Schupp, CEO
Page 16
Strategic priorities: Unchanged CUSTOMERS AT THE CENTRE OF WHAT WE DO Accelerate US Keri Medical Value Strategy Regional share gains Innovation & Digitalisation Improve Cashflow HIGH PERFORMANCE CULTURE with a high-performance team 1616
Page 17
17 Firmly on track to meet our full-year TOUCH projection 17 Annual TOUCH volumes (in thousands of units) 1 KeriMedical sales include its flagship TOUCH® CMC 1 prosthesis for thumb arthritis as well as KeriFlex®, a silicone implant for MCP and PIP finger joints. 0 15 30 45 60 2021 2022 2023 2024 2025 E2026 H1 − Keri Medical continued to grow dynamically. Sales surged by 45% in Medartis's direct-distribution countries (e.g. Austria, Germany and the UK) and by 30% in the business with external distribution partners (incl. the more mature French and Belgium markets). − Initial unit projection for the US rollout raised from 1,200 to 1,800 TOUCH units in 2026.
Page 18
18 Medartis Group with strong presence at CMC1 (Nice) and FESSH congresses (Basel)
Page 19
19 COO MARIO DELLA CASA CFO and US a.i. PETER HACKEL GM Keri Medical Julie Mottet President EMEA MAREIKE LOCH EVP R&D MARC AMMANN CHRO CAROLINE KNOERI CEO MATTHIAS SCHUPP Assistant CEO – Board SecretaryANTONIETTA FASOLIN Executive Management Board as of 1 January 2027 ONE TEAM KeriMedical Advisory Board DOUGAL BENDJABALLAH & BERNARD PRANDI CEO Assistant – Board Secretary Antonietta Fasolin CEO NeoOrtho & EVP LATAM tba CEO Matthias Schupp
Page 20
20 ⎼ Given its strategic relevance for our Group, we have decided that Keri Medical will be represented on the EMB on 1 January 2027 ⎼ Julie Mottet will join the Group EMB, having previously been a member of our EMG ⎼ Keri Medical's operations are scaling to meet future demand Julie Mottet from Keri Medical to join the EMB Julie Mottet CEO Keri Medical
Page 21
21 We are expanding capacity in all our sites Premium Implants & Instrument-Production Warsaw, US Value Implants NeoOrtho, Curitiba, Brazil Implants; KeriMedical, Archamps, France HQ /premium implant production; Basel, Switzerland Complex personalised implants; Gent, Belgium Instruments & implants Keri Medical, Besançon, France
Page 22
22 Keri Medical l Opening of Archamps expansion Slider animation
Page 23
23 New production facility in Besançon due to open in H1 2028
Page 24
24 New NeoOrtho facility officially opened
Page 25
25 New NeoOrtho facility officially opened
Page 26
26 Outlook 2026
Page 27
27 ⎼ ‘Titan Nail’ is an intramedullary implant that stabilises the bone from within rather than through a plate-and-screw construct ⎼ Designed to reduce soft-tissue exposure and operating time in suitable indications ⎼ Delivered via a new procedure kit designed to be flexible and asset-light for hospitals to use ⎼ Important addition to the upper limb portfolio and an improved alternative to the NX nail system previously sourced from a 3rd party vendor ⎼ We will gradually phase out the NX nail and transition to our proprietary technology New ‘Titan Nail’ launched in August l excellent feedback from American surgeons right from the start
Page 28
The new Proximal Humerus system in limited release − Addressing a top-3 indication where we are not present today − New PentaLock locking system for selected indications to compliment the APTUS portfolio − Anatomical plated design to fit individual bone and soft tissue conditions feat. spiral blade for extra stability − Proximal humerus fracture is one of the top 3 indications, where we hold limited share and have ample growth potential
Page 29
1 Organic growth denotes the increase in sales at constant exchange rates (CER), excluding the sales from acquired or sold businesses (i.e. NeoOrtho, KeriMedical, CADskills) in the baseline. NSI's contract manufacturing business and divested NeoOrtho hip business were non-core activities. 29 New Outlook 2026 (barring any unforeseen circumstances) 17 - 19% Core Sales in the high teens at CER ORGANIC1 GROWTH CORE EBITDA MARGIN
Page 30
Pandemic Accelerating momentum Net sales (in CHF million) Core EBITDA-Margin (in %) 30 2019 2020 2021 2022 2023 2024 2025 E2026 130,1 127,6 159,9 182,8 212,0 224,8 269,3 CHF +13% Organic +14% 15.3% 18.4% High teens Organic 17-19%
Page 31
Q&A 31
Page 32
Date Event Destination Broker Broadcasting 18 August 2026 half-year results publication Online Yes 01 September Reverse roadshow Basel Octavian 02 September Non-deal roadshow Geneva ZKB 03 September Non-deal roadshow Paris Octavian 22 September Non-deal roadshow London ZKB 23 September Reverse roadshow Basel Barclays 23 September Best of Switzerland Conference Online UBS 24 September Best of Switzerland Conference Wolfsberg, Switzerland UBS 05 November Swiss Equities Conference Zurich ZKB 09 November Non-deal roadshow Toronto/Montreal Stifel 10 November Non-deal roadshow Chicago Stifel 11 November Stifel Healthcare Conference New York Stifel 19 November Jefferies Healthcare Conference London Jefferies 20 November Non-deal roadshow London UBS 02 March 2026 full-year results publication Basel Yes 22 April Annual General Meeting 2027 Basel Yes Upcoming corporate events 32Investors: Journalists: investor.relations@medartis.com corporate.communication@medartis.com
Page 33
Analyst coverage: For independent research opinions Brokers listed alphabetically Broker Analyst Email Telephone Octavian Sandra Dietschy sandra.dietschy@octavian.ch +41 44 518 08 27 Research Partners AG Eugen Perger eugen.perger@researchpartners.ch +41 44 533 40 30 Stifel Nicolaus Europe Ltd. Edward Hall ed.hall@stifel.com +44 7584 240 168 UBS Tanya Hansalik tanya.hansalik@ubs.com +41-44-239-2053 Zürcher Kantonalbank (ZKB) Michelle Büchler michelle.buechler@zkb.ch +41 44 292 89 46 33
Page 34
THANK YOU! M E D A R T I S . C O M +41 61 633 37 36 info@medartis.com Hochbergerstrasse 60E 4057 Basel/Switzerland 34